- Home
- G vs NUVL Comparison
G vs NUVL Comparison
Compare G & NUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- G
- NUVL
- Stock Information
- Founded
- G 1997
- NUVL 2017
- Country
- G Bermuda
- NUVL United States
- Employees
- G N/A
- NUVL N/A
- Industry
- G Professional Services
- NUVL Biotechnology: Pharmaceutical Preparations
- Sector
- G Consumer Discretionary
- NUVL Health Care
- Exchange
- G Nasdaq
- NUVL Nasdaq
- Market Cap
- G 7.2B
- NUVL 7.2B
- IPO Year
- G 2007
- NUVL 2021
- Fundamental
- Price
- G $38.93
- NUVL $91.03
- Analyst Decision
- G Buy
- NUVL Strong Buy
- Analyst Count
- G 7
- NUVL 12
- Target Price
- G $49.57
- NUVL $123.33
- AVG Volume (30 Days)
- G 1.6M
- NUVL 576.9K
- Earning Date
- G 11-06-2025
- NUVL 10-30-2025
- Dividend Yield
- G 1.76%
- NUVL N/A
- EPS Growth
- G N/A
- NUVL N/A
- EPS
- G 3.01
- NUVL N/A
- Revenue
- G $4,929,034,000.00
- NUVL N/A
- Revenue This Year
- G $7.51
- NUVL N/A
- Revenue Next Year
- G $6.69
- NUVL N/A
- P/E Ratio
- G $12.81
- NUVL N/A
- Revenue Growth
- G 7.40
- NUVL N/A
- 52 Week Low
- G $37.49
- NUVL $55.54
- 52 Week High
- G $56.76
- NUVL $104.90
- Technical
- Relative Strength Index (RSI)
- G 40.44
- NUVL 49.80
- Support Level
- G $37.49
- NUVL $90.00
- Resistance Level
- G $40.07
- NUVL $104.90
- Average True Range (ATR)
- G 0.64
- NUVL 5.10
- MACD
- G 0.02
- NUVL -0.88
- Stochastic Oscillator
- G 44.81
- NUVL 14.67
About G Genpact Limited
Genpact Ltd is a provider of business process management services. Clients are industry verticals and operate in banking and financial services, insurance, capital markets, consumer product goods, life sciences, infrastructure, manufacturing and services, healthcare, and high-tech. Genpact's services include aftermarket, direct procurement, risk and compliance, human resources, IT, industrial solutions, collections, finance and accounting, and media services. Genpact's end market by revenue is India. It is a General Electric spin-off, which is still a large source of revenue for Genpact.
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.